EUCTR2007-006025-27-IT进行中（未招募）不适用
A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Pre- or post-menopausal women with histologically proven, locally advanced
- •(inoperable) or metastatic breast carcinoma.
- •Immunohistochemical receptor status at the last biopsy available:
- •ER and PgR absent (0% of the cells) or
- •ER or PgR Absent or
- •ER and PgR ≤ 50% of the cells
- •Measurable disease
- •Age >18 years
- •Life expectancy of greater than 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous treatment with bevacizumab, EGFR inhibitors or metronomic cyclophosphamide + capecitabine.
- •Immunohistochemical receptor status at the last biopsy available:
- •ER and PgR≥50%
- •Presence of cerebral or leptomeningeal involvement.
研究者
相似试验
进行中（未招募）
不适用
A phase II study evaluating the role of the combination of Vinorelbine,cyclophosphamide and capecitabine administered metronomically, that means low doses daily orally, in patients with advanced breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2010-024266-21-ITISTITUTO EUROPEO DI ONCOLOGIA100
进行中（未招募）
不适用
A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer - NDPre-or post-menopausal women with histologically proven, locally advanced (inoperable) or metastatic breast cancer.EUCTR2009-017083-16-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
1 期
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
进行中（未招募）
1 期
Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumorEUCTR2021-002540-67-FRCentre Oscar Lambret28
已完成
3 期
ANZ 0001 Capecitabine vs CMF in Advanced Breast CancerAdvanced breast cancerACTRN12606000379516Breast Cancer Trials (formerly Australian New Zealand Breast Cancer Trials Group)325